Natco Pharma launches cancer drug Tipanat in India
Hyderabad: Natco Pharma Limited has recently announced that the company has launched a novel fixed-dose combination of Trifluridine + Tipiracil for the first-time in India under the brand name Tipanat as a pack of 20 tablets in a bottle.
Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.
In India, approximately 1,25,000 new cases of the above-mentioned cancers are reported every year. Tipanat is of high importance in not only extending the survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need. NATCO has offered Tipanat at an affordable price.
Medical Dialogues team had earlier reported that Natco Pharma's marketing partner Breckenridge Pharmaceutical, Inc., US had launched the l0 mg strength of Everolimus Tablets (generic for Afinitor'" ) in the US market.
Read also: Natco Pharma marketing partner launches generic version of Afinitor in US
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
